Rigel Pharmaceuticals Future Growth
Future criteria checks 5/6
Rigel Pharmaceuticals is forecast to grow earnings and revenue by 43.3% and 13% per annum respectively. EPS is expected to grow by 41.8% per annum. Return on equity is forecast to be 136.5% in 3 years.
Key information
43.3%
Earnings growth rate
41.8%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 13.0% |
| Future return on equity | 136.5% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 226 | 38 | 39 | N/A | 6 |
| 12/31/2025 | 194 | 20 | 6 | N/A | 6 |
| 12/31/2024 | 169 | 9 | N/A | N/A | 6 |
| 9/30/2024 | 157 | 4 | 10 | 11 | N/A |
| 6/30/2024 | 130 | -14 | -13 | -12 | N/A |
| 3/31/2024 | 119 | -20 | -7 | -7 | N/A |
| 12/31/2023 | 116 | -25 | -21 | -6 | N/A |
| 9/30/2023 | 129 | -24 | -36 | -21 | N/A |
| 6/30/2023 | 121 | -38 | -49 | -33 | N/A |
| 3/31/2023 | 125 | -45 | -67 | -52 | N/A |
| 12/31/2022 | 116 | -59 | -74 | -74 | N/A |
| 9/30/2022 | 86 | -83 | -71 | -71 | N/A |
| 6/30/2022 | 87 | -85 | -68 | -68 | N/A |
| 3/31/2022 | 77 | -85 | -1 | 0 | N/A |
| 12/31/2021 | 139 | -18 | 5 | 6 | N/A |
| 9/30/2021 | 138 | -15 | 8 | 9 | N/A |
| 6/30/2021 | 136 | -8 | -1 | 0 | N/A |
| 3/31/2021 | 131 | -11 | -70 | -69 | N/A |
| 12/31/2020 | 109 | -30 | -53 | -52 | N/A |
| 9/30/2020 | 106 | -28 | -48 | -46 | N/A |
| 6/30/2020 | 108 | -25 | -43 | -41 | N/A |
| 3/31/2020 | 102 | -28 | -46 | -44 | N/A |
| 12/31/2019 | 59 | -67 | -43 | -42 | N/A |
| 9/30/2019 | 82 | -46 | -21 | -20 | N/A |
| 6/30/2019 | 66 | -59 | -26 | -26 | N/A |
| 3/31/2019 | 57 | -64 | -37 | -36 | N/A |
| 12/31/2018 | 45 | -70 | -60 | -59 | N/A |
| 9/30/2018 | 7 | -100 | -91 | -90 | N/A |
| 6/30/2018 | 3 | -93 | N/A | -88 | N/A |
| 3/31/2018 | 1 | -87 | N/A | -80 | N/A |
| 12/31/2017 | 4 | -78 | N/A | -78 | N/A |
| 9/30/2017 | 7 | -68 | N/A | -70 | N/A |
| 6/30/2017 | 10 | -73 | N/A | -75 | N/A |
| 3/31/2017 | 19 | -67 | N/A | -74 | N/A |
| 12/31/2016 | 20 | -69 | N/A | -76 | N/A |
| 9/30/2016 | 26 | -66 | N/A | -77 | N/A |
| 6/30/2016 | 35 | -50 | N/A | -64 | N/A |
| 3/31/2016 | 32 | -51 | N/A | -64 | N/A |
| 12/31/2015 | 29 | -51 | N/A | -23 | N/A |
| 9/30/2015 | 29 | -61 | N/A | -25 | N/A |
| 6/30/2015 | 16 | -75 | N/A | -34 | N/A |
| 3/31/2015 | 10 | -87 | N/A | -35 | N/A |
| 12/31/2014 | 8 | -91 | N/A | -70 | N/A |
| 9/30/2014 | 6 | -85 | N/A | -74 | N/A |
| 6/30/2014 | 6 | -88 | N/A | -76 | N/A |
| 3/31/2014 | 7 | -86 | N/A | -77 | N/A |
| 12/31/2013 | 7 | -89 | N/A | -86 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RI2's forecast earnings growth (43.3% per year) is above the savings rate (1%).
Earnings vs Market: RI2's earnings (43.3% per year) are forecast to grow faster than the German market (20.9% per year).
High Growth Earnings: RI2's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RI2's revenue (13% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: RI2's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RI2's Return on Equity is forecast to be very high in 3 years time (136.5%).